Almirall stock holds recent gains as investors digest half-year figures
Published on 09/20/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall stock (ISIN ES0157097017) finished the September 18, 2026 session on Bolsa de Madrid at EUR 10.44, a decline of 1.51 percent from the prior close after a drop of EUR 0.16 that left the shares slightly below recent highs.
Half-year 2026 results underpin valuation
The Spanish dermatology specialist Almirall, S.A. reported its most recent half-year 2026 figures with solid top-line growth and improved profitability compared to the prior year period. According to Almirall for the first half of 2026, revenues reached EUR 478.9 million, up 7.2 percent from EUR 446.8 million in the first half of 2025, driven mainly by prescription dermatology products in Europe and the United States. The company reported EBITDA of EUR 119.4 million for the first half of 2026, an increase of 12.1 percent compared with EUR 106.4 million in the same period of 2025, as higher gross profit and disciplined operating expenses supported margin expansion.
Net profit also improved: Almirall posted net income of EUR 54.2 million in the first half of 2026, up 18.3 percent from EUR 45.8 million in the first half of 2025, reflecting both revenue growth and lower financial expenses. According to Almirall, the company confirmed its full-year 2026 guidance, targeting low to mid-single-digit revenue growth and an EBITDA margin in the high twenties percent, which investors now weigh against the current share price level.
Stock reaction to recent rally and guidance
Following the publication of the half-year 2026 results and confirmation of guidance, Almirall stock has staged a rally in recent sessions before giving back a small part of the gains. As a corporate news overview from Ad-hoc-news noted on September 19, 2026, the shares closed at EUR 10.44 on September 18, 2026, down 1.51 percent from the prior close, after a period in which the stock had moved higher on optimism around ongoing margin improvements. The closing level of EUR 10.44 remains meaningfully above the lows seen earlier in 2026, suggesting that the market continues to price in the company’s progress in dermatology and its pipeline of new treatments.
In terms of balance sheet, Almirall reported net debt of EUR 371.0 million as of June 30, 2026, compared with EUR 402.5 million one year earlier, implying a reduction of EUR 31.5 million driven by operating cash generation and disciplined investment spending, according to Almirall. For investors, the combination of growing EBITDA and declining net debt is an important signal that the company can support continued investment in its dermatology portfolio while maintaining financial flexibility.
Analyst perspective and risk factors
Recent analyst commentary has focused on how sustainable Almirall’s margin gains will be if competition in key dermatology indications intensifies. According to a sector note on European specialty pharma from a large international investment bank published in mid-September 2026 and cited by Almirall, consensus expects mid-single-digit annual revenue growth over the next two years, supported by recently launched dermatology brands. However, the note also highlights pricing pressure in mature markets and the need for continued successful product launches to offset generic erosion in legacy brands.
One of the key risks investors monitor is regulatory and reimbursement uncertainty for new dermatology therapies across major European markets. As the same investor relations overview from Almirall explains, the company’s pipeline includes several late-stage assets, and delays in reimbursement decisions or stricter cost-containment measures could weigh on future revenue growth. For holders of Almirall stock, these dynamics mean that the strong first-half numbers and reduced net debt must be considered alongside the competitive and regulatory landscape in dermatology.
Almirall stock price level and trading context
On its primary listing on Bolsa de Madrid, Almirall stock closed at EUR 10.44 on September 18, 2026, with a daily decline of 1.51 percent and a price move of EUR minus 0.16 compared with the previous close, according to price data for that completed trading day. At this level, the shares trade at a moderate distance below the highs reached earlier in 2026 and above the lows of the past twelve months, with a market capitalization in the mid-single-digit billions of EUR as of September 18, 2026, based on the latest available price and share count.
Key data on Almirall stock
- Company: Almirall, S.A.
- ISIN: ES0157097017
- Ticker: ALM
- Trading venue: Bolsa de Madrid
- Price (as of September 18, 2026): 10.44 EUR
- Market capitalization: approximately 1,900,000,000 EUR (as of September 18, 2026)
- Sector / Industry: Pharmaceuticals / Dermatology
- Index membership: IBEX Medium Cap
